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Total IgEAbstract Background: The mechanisms of intrinsic or non-allergic asthma remain uncertain as
allergens have no obvious role in driving the inflammatory process in the airways. This study
was designed to test the possible presence of an autoimmune pathogenesis of bronchial asthma
and to investigate the similarities and differences between allergic and non-allergic asthma.
Design: Cross-sectional prospective cohort study.
Subjects and methods: 50 asthmatic women and 30 healthy control women were tested for thy-
roid function, anti-TPO, anti-CK18 autoantibodies, and total IgE measurements. Pulmonary func-
tion tests, skin-prick test and history of asthma risk factors were done for asthmatic women.
Results: Allergic asthma were found in half of the asthmatic patients and the other half (25/50)
were non-allergic according to the results of skin-brick test and serum level of IgE. The thyroid func-
tion tests were not statistically different between asthmatic and control groups as well as between
non-allergic and allergic asthma groups (P> 0.05). Serum anti-TPO autoantibodies and anti-
CK18 autoantibodies’ levels were significantly higher in asthmatic patients than the control group
and also in non-allergic asthma patients than allergic asthma patients. In asthmatic patients serum
anti-TPO autoantibodies showed negative correlation with FEV1 (pre- and post) and serum IgE.
Conclusion: Positive anti-TPO autoantibodies and anti-CK18 autoantibodies in asthmatic
patients and their higher level in the non-allergic asthma group may strengthen the presence of a hid-
den autoimmune phenomenon in non-allergic asthma.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).18; IgE,
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Bronchial asthma is as a heterogeneous disease, usually
characterized by chronic airways inflammation. It is defined
by the history of respiratory symptoms such as wheezes,
shortness of breath, chest tightness and cough that vary over
time and in intensity, together with variable expiratory airflow
limitation [1].
Asthma is a problem worldwide with an estimated 300
million affected individuals [2]. The global prevalence of
asthma range from 1% to 18% of the population in different
countries [3,4]. In Egypt, the bronchial asthma is a significant
health problem among school children, and the prevalence was
7.7% [5]. Annual world deaths from asthma have been esti-
mated at 250,000. Asthma is a major cause of absence from
work in many countries [6–8].
Malfunction of the immune system is known in three main
conditions: immunodeficiency, allergy, and autoimmunity.
The appearance of autoimmunity and allergies has not been
well appreciated. Recently, there are reports on the appear-
ance of allergies concomitantly with autoimmunity, but the
relationship is poorly understood. Allergy and autoimmunity
are two potential outcomes of dysregulated immunity. Both
are characterized by localized inflammation that leads to
the injury and/or destruction of target tissues [9]. The allergic
response to common environmental agents (allergens) has
been regarded as an important mechanism in the develop-
ment of airway inflammation of patients with asthma. How-
ever, allergic sensitization cannot be detected in a significant
number of adult patients with asthma [10]. Non-allergic
asthma usually begins at an older age and is clinically more
severe than allergic asthma. Non-allergic asthma has been
referred to as ‘‘intrinsic asthma” on the basis of a belief that
there must be an etiologic agent in the patient’s own body.
However, the ‘‘intrinsic” etiology has not yet been defined
[11].
One of the most important causes of thyroid diseases is
autoimmunity in origin, and it seems that people with thyroid
diseases present more signs of asthma. A little is known about
the relation between thyroid disease and allergic diseases. The
pathogenic mechanism for relationship between thyroid dys-
function and severity of asthma signs is not clearly understood.
Knowledge of the presence of thyroid disease in patients with
bronchial asthma is important. The reason is that hypothy-
roidism may coexist with allergic diseases such as bronchial
asthma, while hyperthyroidism may be associated with a lower
incidence of allergies. Some studies have shown that hypothy-
roidism ameliorates and hyperthyroidism exacerbates bron-
chial asthma [12].
The idea of the possible involvement of an autoimmune
mechanism in the pathogenesis of asthma has been proposed
by previous studies that demonstrated high incidences of
circulating autoantibodies to bronchial mucosa tissue (as
anti-CK18 autoantibodies) in patients with asthma, especially
in patients with non-allergic asthma [13–15].
This study was designed to investigate the frequency of
autoimmune phenomena with and without thyroid
diseases in women suffering from bronchial asthma by measur-
ing serum level anti-TPO autoantibodies and anti-CK18
autoantibodies.Subjects and methods
This study was conducted on 80 women over 18 years. Fifty of
them had bronchial asthma whatever severity and thirty of
them were healthy non-asthmatic. Women who attended to
outpatient clinic at chest department and internal medicine
department of El-Minia University Hospital were invited to
participate in the study. The study was approved by the hospi-
tal’s research ethics board.
Exclusion criteria
Women who had the diagnosis of COPD, connective tissue
diseases, congestive heart failure, chronic renal failure or pos-
itive history of definite thyroid diseases or being under treat-
ment were excluded. Pregnant and smoking women were
also excluded.
The control group consisted of 30 women selected from
people who participated in a field trial study. This group had
no symptoms or signs of asthma disease in addition to all
the above exclusion criteria.
The asthmatic patients were selected based on having char-
acteristic respiratory symptoms such as wheezing, dyspnea,
chest tightness or coughing and variable expiratory airflow
limitation. Variable expiratory airflow limitation was con-
firmed by spirometry (ZAN 300, Germany). Reversibility
refers to rapid improvement in FEV1 (12% and 200 ml) mea-
sured within minutes after inhalation of 400 lg of salbutamol
[16]. Asthma severity was graded based on guidelines for diag-
nosis and treatment of asthma. Four groups; mild intermittent,
mild persistent, moderate persistent and severe persistent were
considered [17].
All asthmatic subjects underwent a skin-prick test with 12
common aeroallergens based on common aeroallergens in
our region: mites, molds, pollens, animal dander, pigeon,
house dust, feather, cats, strew and Candida. Histamine and
saline were used as positive and negative controls. Patients
with asthma were classified as having allergic asthma when
the wheal diameter of any one allergen was greater than
3 mm over the negative control (normal saline) and there
was a definite clinical history or objective evidence of asth-
matic response induced by allergen exposure. Non-allergic
asthma was defined as there being no positive skin reaction
to any of the 12 common aeroallergens in the presence of a
positive histamine control and serum total IgE concentration
being within the normal range (less than 180 IU/ml). All
patients with asthma had not received systemic steroid treat-
ment for the 4 weeks before the study.
Five ml of venous blood was taken by sterile venipuncture
after informed consent of all participants and divided as fol-
lows: one ml on EDTA for CBC, 4 ml on plasma tube was left
to be collected and centrifuged to separate serum, and then
serum was freezed at 70 C for assay of anti-CK18 autoanti-
bodies, total IgE, Anti-TPO, total T4 and TSH. All were mea-
sured by the EIA (Enzyme immune-assay) method using
Huma reader, Germany.
Kits of Anti-TPO autoantibodies were supplied by Bios,
USA, chemux Bioscience. Kits of autoantibodies to anti-CK
autoantibodies were supplied by orgentec, diagnostic, Ger-
many. Kits of total IgE were supplied by orgentec, diagnostic,
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USA, chemux Bioscience. CBC was determined by automated
cell counter sysmex KX-2IN (TAO medical incorporation,
Japan).
Anti-TPO autoantibodies >50 IU/ml were considered as
positive. Hypothyroidism was based on TSH> 10 IU/ml
and total T4 < 4.5 lg/dl 4. The normal level of total IgE
was up to 180 IU/ml. The normal level of anti-CK autoanti-
bodies was up to 13.4 pg/ml.
Principles of the anti-CK autoantibodies test: The microti-
ter plate provided in this kit has been pre-coated with an anti-
body specific to keratin, type 1 cytoskeletal 18. Standards or
samples are then added to the microtiter plate wells with a
biotin-conjugated poly clonal antibody preparation specific
for keratin, type 1 cytoskeletal 18 and Avidin conjugated to
Horseradish Peroxidase(HRP) is added to each microplate
well and incubated. Then a TMB substrate is added to each
well. Only those wells that contain keratin, type 1 cytoskeletal
18, biotin-conjugated antibody Avidin will exhibit a change in
color. The enzyme substrate reaction is terminated by the addi-
tion of sulfuric acid solution and color change is measured
specterophotometrically at a wavelength of 450 nm ± 2 nm.
The concentration of keratin, type 1 cytoskeletal 18 in the sam-
ples is then determined by comparing the O.D. of the samples
to the standard curve.
Statistical analysis
Analysis of data was done by SPSS (statistical program for
social science, version 17). The following statistical methods
were used: Description of quantitative variables as means,
SDs, and ranges; description of qualitative variables as num-
bers and percentages; chi-square test for comparisons of qual-
itative variables between groups; unpaired t-tests to compare
two groups; Spearman correlation coefficient to rank different
variables as either positive or inverse. The results were consid-
ered to be statistically significant at a P value < 0.05.
Results
The present study included 80 subjects (50 patients with bron-
chial asthma and 30 control healthy subjects). Asthmatic
patients were divided into; 25 (50%) patients had allergic
and the others were non-allergic asthma, according to the
results of skin-brick test and serum level of total IgE.
In the present study 42 (21/50)% of asthmatic women had
allergic rhinitis, 36 (18/50)% had chronic sinusitis and 10
(5/50)% had urticaria. The women with non-allergic asthma
had statistically significant lower history of allergic rhinitis,
chronic sinusitis, urticaria and family history than those with
allergic asthma. Within asthmatic women; 62% of lived in
rural areas, 32% were bird breeders and 48% had history of
dust exposure (Table 1).
Asthmatic patients had a significantly higher total IgE
(P 0.001), anti-TPO (P 0.001) and anti-CK18 autoantibodies
(P 0.03) than control subjects (Table 4). Non-allergic asthma
patients had a significantly lower eosinophil count (P 0.002),
higher pre- and post-bronchodilator FVC (P 0.04 for both),
lower total IgE (P 0.001), and higher anti-TPO autoantibodies
(P 0.03) and anti-CK18 autoantibodies (P 0.04) than those
with allergic asthma (Table 5).As regards thyroid function in the present study; there were
three hypothyroid laboratory abnormalities in the asthma
group (two in non-allergic asthma and one in allergic asthma)
and none in the control group, and this difference was not sta-
tistically significant (P> 0.05) (Tables 2 and 3). There were
not statistical differences between asthmatic and control
groups as well as between non-allergic and allergic asthma
groups as regards both total T4 and TSH and the mean values
of both were within normal range (Tables 4 and 5).
A positive anti-TPO autoantibodies’ serum level (>50 IU/
ml) was found in 20% of women in the asthma group and
6.7% of control groups (Table 2), but this difference was sta-
tistically non-significant (P> 0.05). Also, positive anti-TPO
autoantibodies were found in 28% of women in the non- aller-
gic asthma group and 12% of patients in the allergic asthma
group (Table 3) and this difference was statistically non-
significant (P> 0.05).
A positive anti-CK18 autoantibodies’ serum level (>13 IU/
ml) was found in 16% of women in the bronchial asthma
group and 10% of the control groups (Table 2), but this differ-
ence was statistically non-significant (P> 0.05). On the other
hand, 40% of women in the non-allergic asthma group and
12% of patients in the allergic asthma group had positive
anti-CK18 autoantibodies’ levels (Table 3) and this difference
was statistically significant (P 0.01).
There was a significantly negative correlation serum anti-
TPO level and FEV1 (pre- and post-) Figure 1. There was also
a significantly fair negative correlation serum anti-TPO level
and total IgE (Figure 2). There was an insignificant correlation
between anti-TPO and anti-CK18 autoantibodies and thyroid
function (Table 6). There was an insignificant correlation
between serum anti-CK18 autoantibodies’ level and most of
laboratory, and pulmonary function parameters in asthmatic
patients except a positive correlation with post- bronchodilator
PEF25–75.
There was a significant association between severity of
bronchial asthma and anti-TPO autoantibodies’ level (P
0.03), but there was no significant association between severity
of bronchial asthma and anti-CK18 autoantibodies’ level
(P= 0.6) (Table 7).
Discussion
Among the fifty asthmatic patients, 50% patients were found
to have allergic asthma and the other 50% had non-allergic
asthma according to the results of both skin-brick test and
serum level of IgE. The positivity of at least one skin prick test
is usually used in epidemiology as a single diagnostic criterion
for atopy. However, we chose two diagnostic criteria to obtain
contrasted groups and to lower the risk of misclassification of
patients.
In the present study we found that 50% (25 patients) of
asthmatic patients were non-allergic. This proportion is high
as the relative prevalence of non-allergic asthma is considered
to reach 10%. This result is in agreement with Romanet–Man-
ent et al., [18]. In similar studies the non-allergic reached up-to
30% [19]. The relatively high proportion of non-allergic asth-
matics in our study is probably related to the hospital-based
recruitment.
The importance of positive family history in classifying
patients to allergic and non-allergic asthma is outlined in
Table 1 Descriptive data of asthmatic patients and comparison between allergic and non-allergic asthma groups.
All asthmatic (n 50) Allergic asthma (n 25) Non-allergic asthma (n 25) P value
Age 38.7 ± 11.7o 39.72 ± 11.7 37.6 ± 11.7 0.5
Residence Rural 31 (62%)oo 17 (68%) 14 (56%) 0.5
Urban 19 (38%) 8 (32%) 11 (44%)
Risk factors Bird breeding 16 (32%) 10 (40%) 6 (24%) 0.3
Dust exposure 24 (48%) 14 (56%) 10 (40%) 0.3
Clinical data Cough 38 (76%) 21 (84%) 17 (68%) 0.3
Dyspnea 50 (100%) 25 (100%) 25 (100%) 0.6
Wheeze 48 (96%) 25 (100%) 23 (92%) 0.5
Allergic rhinitis 21(42%) 17 (68%) 4 (16%) 0.001*
Sinusitis 18 (36%) 14 (56%) 4 (16%) 0.001*
Urticaria 6 (12%) 6 (24%) 0 0.02*
Nocturnal attack 45 (90%) 25 (100%) 20 (80%) 0.5
Family history 14 (28%) 11 (44%) 3 (12%) 0.03*
Disease duration (yrs.) 7.53 ± 7.13o 7.79 ± 7.21 7.28 ± 7.19 0.8
Medication Regular use 11 (22%) 8 (32%) 3 (12%) 0.1
ICS 24 (48%) 17 (68%) 7 (28%) 0.01*
SABA 40 (80%) 23 (57.5%) 17 (68%) 0.05*
LABA 31 (62%) 19 (76%) 12 (48%) 0.009*
Systemic steroids 4 (8%) 3 (12%) 1 (4%) 0.6
Antihistaminic 3 (6%) 3 (12%) 0 0.2
Leukotriene modifiers 3 (6%) 3 (12%) 0 0.2
Theophyllines 15 (30%) 11 (44%) 4 (16%) 0.01*
o Data presented as mean ± SD.
oo Data presented as number (percentage).
* Significant P< 0.05.
Table 2 Comparison of frequency of anti-TPO and anti-
CK18 autoantibodies and hypothyroid abnormalities in asthma
and control groups.
Control
group
(n 25)
Asthma
group
(n 25)
P value
Anti-TPO autoantibodies
> 50 IU/ml
2 (6.7%) 10 (20%) 0.1
Anti-CK18 autoantibodies
> 13 pg./ml
3 (10%) 13 (16%) 0.08
Hypothyroid 0 (0%) 3 (6%) 0.2
Table 3 Comparison of frequency of anti-TPO and anti-
CK18 autoantibodies and hypothyroid abnormalities abnor-
mality in allergic and non-allergic asthma groups.
Allergic asthma
(n 25)
Non-allergic
asthma (n 25)
P value
Anti-TPO> 50 IU/ml 3 (12%) 7 (28%) 0.07
Anti-CK18 > 13 pg/ml 3 (12%) 10 (40%) 0.01*
Hypothyroid 2 (8%) 1 (4%) 0.95
* Significant P< 0.05.
Table 4 Comparison between asthmatic patients and control
as regards serum level of different laboratory tests.
Asthma
group
(n 25)
Control
group
(n 25)
P value
Total IgE IU/ml 280.8 ± 313.3 45.1 ± 38.3 0.001*
Anti-TPO autoantibodies
IU/ml
44.7 ± 31.9 23.0 ± 20.7 0.001*
Anti-CK18 autoantibodies
pg/ml
22.1 ± 30.8 9.7 ± 5.1 0.03*
Total T4 lg/dl 8.9 ± 2.3 7.8 ± 2.1 0.1
TSH lg/dl 1.89 ± 1.69 1.81 ± 0.52 0.2
* Significant P< 0.05.
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proposed stronger familial association asthma than in non-
atopic asthma in adults [20]. Strong genetic predisposition toatopy and allergy indicates that atopic asthma in adults is
more a family associated phenotype. In our study, positive
family history was found in 44% of allergic asthma and 12%
of non-allergic asthma and this difference was statistically sig-
nificant (P= 0.03).
In the present study, there was a significant increase in the
prevalence of allergic symptoms as allergic rhinitis
(P= 0.001), allergic sinusitis (P= 0.001) and urticaria
(P= 0.02) in allergic asthma than non-allergic asthma. In a
study from an Iowa population, 78% of allergic asthmatics
were rhinitic [21]. Pedersen et al. found a prevalence of 28%
rhinitic patients in an asthmatic population [22]. In study of
Romanet et al. [18], and Leynaert et al. [23], the prevalence
of rhinitic symptoms was similar in both groups, irrespective
Table 5 Comparison between mean levels of different labo-
ratory parameters of allergic and non-allergic asthma groups.
Allergic
asthma
(n 25)
Non-allergic
asthma
(n 25)
P value
Hb% 12.2 ± 1.1 11.9 ± 0.9 0.5
WBCs  103 7.3 ± 3.1 6.8 ± 2.4 0.4
Eosinophils% 1.3 ± 0.5 1.0 ± 0.1 0.002*
Pre-bronchodilator FVC% 79.6 ± 8.7 84.3 ± 7.4 0.04*
Post-bronchodilator
FVC%
88 ± 6.2 91.7 ± 6.4 0.04*
Pre-bronchodilator
FEV1%
59 ± 11.7 61.24 ± 11.4 0.5
Post-bronchodilator
FEV1%
74.3 ± 11.3 75.8 ± 10.3 0.6
Pre-bronchodilator
PEF25–75%
47.1 ± 15.1 56.2 ± 19.1 0.06
Post -bronchodilator
PEF25–75%
64.1 ± 15.1 71.2 ± 14.9 0.1
Total IgE IU/ml 503.1 ± 310.1 58.5 ± 35.9 0.001*
Anti-TPO autoantibodies
IU/ml
34.8 ± 23.6 54.6 ± 36.3 0.03*
Anti-CK18 autoantibodies
pg/ml
13.6 ± 9.9 30.7 ± 4.1 0.04*
Total T4 lg/dl 8.8 ± 2.9 8.9 ± 3.7 0.8
TSH lg/dl 1.81 ± 1.48 1.97 ± 1.91 0.7
* Significant P< 0.05.
Figure 2 Correlation between anti-TPO and IgE.
Figure 1 Correlation between anti-TPO and post-bronchodila-
tor FEV1.
Autoantibodies and bronchial asthma 11of allergic status. The authors found that the probability of
displaying asthma among non-allergic subjects was strongly
associated with perennial rhinitis, and also are probably due
to sinusal pathology. This is suggested by the higher preva-
lence of nasal polyposis and sinusitis in this group.
In the present study, there was a significant statistical eleva-
tion of total IgE level in patients with bronchial asthma than in
healthy subjects and in patients with allergic asthma than those
with non-allergic asthma (P< 0.001 for both). These results
agree with those of Takeoka and colleagues and Abd El-Aziz
et al. [24,25].
As regards the pulmonary function tests in this study,
there was non-significant difference in FEV1 in non-allergicasthmatic patients compared to the allergic asthma allergic
asthmatic (P 0.5). This result is in agreement with Maria study
[26]. Inouye et al. compared asthma severity in two groups of
asthmatics with negative and positive skin tests to
aeroallergens. They found greater exercise limitation, more fre-
quent asthma-related symptoms, and a greater use of oral ster-
oids in the negative skin test group, suggesting more severe
asthma. Nevertheless, these differences disappeared after
adjusting for age and asthma duration [27]. Furthermore,
bronchial obstruction assessed by FEV1 was not significantly
different between both groups. Accordingly, Cline et al. [28]
did not find positivity of skin tests to be related to FEV1
nor to asthma severity.
In the present study, anti-TPO autoantibodies were statisti-
cally higher in bronchial asthma patients than in healthy sub-
jects (P< 0.001). These results agree with previous studies
[25,29,30]. The explanation was that the Th2 response-
enhanced antibodies (as in asthma and other allergic diseases),
and IL4, IL5, and IL13 (involved in allergic diseases) stimulate
B cells to secrete thyroid antibodies, which in turn decrease
thyroid hormone synthesis and secretion [31].
In our study, anti-TPO autoantibodies’ level had significant
negative correlation with total IgE in bronchial asthma
patients (r= 0.344, P 0.01) and these results confirm that
the changes in serum levels of antibodies can be used as an
indicator of allergic and non-allergic asthma. These results
are similar to those of Abd El-Aziz, et al. (r= 0.56,
P< 0.05) [25].
As regards thyroid function, there were no statistical differ-
ences between asthmatic and control groups as well as between
non-allergic and allergic asthma groups as regards both total
T4 and TSH suggesting that asthma was not associated with
changes in thyroid function. Abd El-Aziz et al. reported simi-
lar results [25]. Biscaldi and colleagues reported that T3 and T4
levels were higher in a control group than in asthmatic
patients; but still, the asthmatic patients’ thyroid hormone
levels were within the reference range, suggesting that asthma
was not associated with changes in thyroid function [32].
Landyshev and colleagues reported that thyroid function
undergoes biphasic changes in bronchial asthma patients
[33]. They also reported that as patients with mild bronchial
asthma progressed to paroxysmal exacerbation of their
Table 6 Correlation between anti-TPO autoantibodies, anti-CK18 autoantibodies and total IgE and other parameters in all asthmatic
patients.
Anti-TPO autoantibodies Anti-CK18 autoantibodies Total IgE
r P r P r P
Eosinophils% 0.123 0.4 0.127 0.3 0.398 0.004*
Pre-bronchodilator FVC% 0.219 0.1 0.232 0.1 0.156 0.3
Post-bronchodilator FVC% 0.142 0.3 0.183 0.2 0.069 0.6
Pre-bronchodilator FEV1% 0.372 0.008* 0.103 0.5 0.044 0.7
Post-bronchodilator FEV1% 0.452 0.001* 0.074 0.6 0.045 0.8
Pre-bronchodilator PEF25–75% 0.157 0.3 0.185 0.2 0.223 0.1
Post-bronchodilator PEF25–75% 0.184 0.2 0.315 0.02* 0.234 0.1
Total IgE IU/ml 0.344 0.01* 0.160 0.3 1.00
Anti-TPO autoantibodies IU/ml 1.00 0.259 0.05* 0.344 0.01*
Anti-CK18 autoantibodies pg/ml 0.259 0.05 1.00 0.160 0.3
Total T4 lg/dl 0.109 0.4 0.001 0.9 0.044 0.8
TSH lg/dl 0.131 0.2 0.032 0.7 0.022 0.8
* Significant P< 0.05.
Table 7 Relationship between severity of allergic asthma and anti-TPO and anti-CK18 autoantibodies’ serum levels.
Total Mild intermittent
(N= 0)
Mild persistent
(N= 1)
Moderate persistent
(N= 27)
Severe persistent
(N= 22)
P value
Negative anti-TPO autoantibodies 6 50 IU/ml 40 0 (0%) 1 (100%) 25 (93.6%) 14 (63.6%) 0.03*
Positive anti-TPO autoantibodies > 50 IU/ml 10 0 (0%) 0 (0%) 2 (6.4%) 8 (36.4%)
Positive anti-CK18 autoantibodies < 13.4 pg/ml 37 0 (0%) 1 (100%) 21 (77.8%) 15 (68.2%) 0.6
Negative anti-CK18 autoantibodies > 13.4 pg/ml 13 0 (0%) 0 (0%) 6 (22.2%) 7 (31.8%)
* Significant P< 0.05.
12 H.A. Mohammad et al.asthma, hypo-function of the patients’ thyroid glands
developed.
Also, we found the frequency of hypothyroidism was not
statistically-different between the asthmatic group and control
groups. Mitra and colleagues reported similar results [34]. In
contrast, in the study of Jerez et al. on 49 asthmatics the preva-
lence of hypothyroidism was higher in the test group [35]. This
may be due to lower sample size in the present study.
In our study, anti-CK18 autoantibodies’ level in bronchial
asthma patients was statistically higher than in healthy sub-
jects (P< 0.03). Anti-CK18 autoantibodies’ level was statisti-
cally higher than in non-allergic asthma than in allergic asthma
(P< 0.04). Also, positive anti-CK18 autoantibodies’ level
(>13) was present in 40% of non-allergic asthma patients
and 12% of allergic asthma patients which was statistically sig-
nificant (P 0.01). Dong, et al. [36] reported similar results as
they reported that circulating IgG autoantibodies to the anti-
CK18 were detected in 43% of patients with non-allergic
asthma, 11% of patients with allergic asthma and 9% of
age-matched healthy volunteers (P< 0.005).
Another study reported that circulating autoantibodies
against bronchial epithelial cells was detected in 9.1% (2 of
22) of non-atopic asthma (which is relatively low) and in none
of 22 atopic asthma patients and of 22 healthy control subjects
[37].
The identification of anti-CK18 autoantibodies as a bron-
chial epithelial auto-antigen associated with non-allergic
asthma might provide a clue to exploring the autoimmune
hypothesis in the pathogenesis of non-allergic asthma or itcould be just a reflection of epithelial damage in patients with
asthma [38].
Increased concentrations of circulating IgG antibodies
against bovine cytokeratin 18 antigen have been reported in
patients with idiopathic pulmonary fibrosis and autoimmune
hepatitis [39,40], and increased concentrations of circulating
IgA antibodies to bovine cytokeratin 18 antigen have also been
reported in patients with rheumatoid arthritis [41]. These find-
ings suggest that the anti-CK18 antigens may not be specific to
non-allergic asthma.
The present study found association between severity of
bronchial asthma and anti-TPO autoantibodies’ level (Tables
6 and 7), but there was no association between severity of
bronchial asthma and anti-CK18 level. Mitra et al. [34] found
no association between severity of bronchial asthma and anti-
TPO autoantibodies’ level (P= 0.54). This difference may be
related to the small number of our studied patients.
IgG antibodies from patients with non-allergic (intrinsic)
asthma have recently been shown to have cytotoxic effects
on epithelial cells, whereas these antibodies are not found in
extrinsic asthma. It is possible that these autoantibodies dam-
age airway epithelial cells so that super-antigen producing
organisms are able to infect the airway surface more easily [42].Conclusions
Asthma might just be a syndrome including various heteroge-
neous diseases regarding etiology, natural history, and sever-
Autoantibodies and bronchial asthma 13ity. Our study suggests the possible existence of a subgroup of
patients with asthma characterized by the presence of autoan-
tibodies to bronchial epithelial antigens. We identified anti-
CK18 autoantibodies (as an antibody response to bronchial
epithelial autoantigens) and anti-TPO autoantibodies (as thy-
roid autoantibody) associated with non-allergic asthma. Fur-
ther studies are needed to determine the significance of
autoimmunity in non-allergic asthma.
Limitations of the study include performing the study on
females, small sample size. Also, some other factors which
could affect the anti-TPO and anti-CK18 autoantibodies are
not included in the study.
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